Regeneron and Sanofi Announce Mixed Results from Phase 3 AERIFY Trials for Itepekimab in COPD Patients
30/5 07:10
The AERIFY-1 trial showed significant reduction in COPD exacerbations, while AERIFY-2 did not meet its primary endpoint....
|
|
|
30/5 07:10
The AERIFY-1 trial showed significant reduction in COPD exacerbations, while AERIFY-2 did not meet its primary endpoint....